

## 2017 Interim Financial Report

**Lyon, September 25<sup>st</sup>, 2017 - AMOEBA (FR0011051598 - AMEBA)**, a French company that develops a biological biocide capable of eliminating waterborne bacterial risk and wound care applications, announced today that it has published its Interim Financial Report for 2017.

AMOEBA's shareholders are informed that the interim financial report for the 2017 financial year ending on December 31<sup>st</sup>, 2017), can be found at the company website: <http://www.amoeba-biocide.com/en/regulatory-information-and-financial-documents>

This report includes:

- Interim Activity Report
- Condensed Interim Financial Statements
- Certification of the person responsible for the interim financial report
- Statutory Auditors' Review Report on the interim financial information

**AMEBA**  
LISTED  
EURONEXT

### About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating waterborne bacterial risk in water treatment and wound care applications. Our solutions represent alternatives to chemical products widely used in the cooling water treatment and the wound care market. In a global market for chemical biocides estimated to be worth EUR 21 bn<sup>(1)</sup> AMOEBA is focusing on the industrial cooling tower application estimated at EUR 1.7 bn<sup>(2)</sup>. Similarly, in a global wound care market estimated at EUR 15.2bn<sup>(3)</sup>, AMOEBA is targeting the chronic wound care market in the USA, estimated to be worth EUR 751 million<sup>(4)</sup>. The use of *Willaertia magna C2c Maky* in health care products will be subject to FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological biocide for water treatment, BIOMEBA, has not yet been granted marketing authorization in the USA, Europe and Canada. AMOEBA is taking the required regulatory steps to be granted marketing authorization in those regions for the use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. More information on [www.amoeba-biocide.com](http://www.amoeba-biocide.com).

(1) *marketsandmarkets.com*, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

(2): Amoéba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013



(3) *M. Diligence*, "Wound Management: An \$18.5 billion+ worldwide market in 2021," *MedMarket Diligence*, 10 June 2013. [Online]. Available: <http://blog.mediligence.com/2013/06/10/wound-management-an-18-5-billion-worldwide-market-in-2021/>. [Accessed 14 February 2017].

(4) *BCC Research*, "Markets for Advanced Wound Management Technologies," Wellesley, MA, 2017.

### **Contacts :**

#### **AMOEBA**

Nathalie COMBROUSSE  
Marketing Communication Manager  
Tel. : +33 (0)4 81 09 18 15  
nathalie.combrousse@amoeba-biocide.com

#### **ACTIFIN**

Ghislaine GASPERETTO  
Financial Communication  
Tel. : +33 (0)1 56 88 11 11  
ggasparetto@actifin.fr